Siena, S., Yamaguchi, K., Ruffinelli Rodriguez, J. C., Corral de la Fuente, E., Kuboki, Y., Cremolini, C., … Masuishi, T. (2024). 505O Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreaK 101 study. In Annals of Oncology (Vol. 35, pp. S429–S430). Elsevier BV. https://doi.org/10.1016/j.annonc.2024.08.574

Siena, S., K. Yamaguchi, J. C. Ruffinelli Rodriguez, E. Corral de la Fuente, Y. Kuboki, C. Cremolini, I. Victoria Ruiz, et al. “505O Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreaK 101 study.” In Annals of Oncology, 35:S429–30. Elsevier BV, 2024. https://doi.org/10.1016/j.annonc.2024.08.574.

Siena S, Yamaguchi K, Ruffinelli Rodriguez JC, Corral de la Fuente E, Kuboki Y, Cremolini C, et al. 505O Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreaK 101 study. In: Annals of Oncology. Elsevier BV; 2024. p. S429–30.

Siena, S., et al. “505O Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreaK 101 study.” Annals of Oncology, vol. 35, Elsevier BV, 2024, pp. S429–30. Crossref, doi:10.1016/j.annonc.2024.08.574.

Siena S, Yamaguchi K, Ruffinelli Rodriguez JC, Corral de la Fuente E, Kuboki Y, Cremolini C, Victoria Ruiz I, Elez Fernandez ME, Strickler JH, Furqan M, Bashir B, Nduka C, Hippenmeyer J, Chan E, Xia C, Masuishi T. 505O Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C–mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreaK 101 study. Annals of Oncology. Elsevier BV; 2024. p. S429–S430.